This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Greenberg, P. L. Articles by Mosny, S. Search for Related Content PubMed PubMed Citation Articles by Greenberg, P. L. Articles by Mosny, S.

Cytotoxic Effects of 1-ß-D-Arabinofuranosylcytosine and 6-Thioguanine in Vitro on Granulocytic Progenitor Cells¹

Department of Medicine, Veterans Administration Hospital and Stanford University School of Medicine, Palo Alto, California 94304

We have utilized an in vitro clonogenic assay of mouse and human marrow granulocytic progenitor cells to determine the cytotoxic effects on granulopoiesis of the chemotherapeutic agents 1-ß-D-arabinofuranosylcytosine (ara-C) and 6-thioguanine. Concentration- and time-dependent decrements to plateau levels of granulocytic colony-forming capacity occurred. The sequence of drug administration was important, and synergistic cytotoxicity was noted when certain schedules of ara-C and 6-thioguanine combinations were used. Endotoxin-stimulated colony-forming cells had increased sensitivity to the in vitro ara-C exposure. High or intermittent doses of ara-C demonstrated enhanced cytotoxicity when short exposure times (1 to 8 hr) were utilized, whereas low doses were markedly cytotoxic with prolonged exposure (10 days). Normal and leukemic human colony-forming cells had similar susceptibility to the cytotoxic effects of ara-C. Exposure of granulocytic precursors to these drugs in vitro produced effects similar to those previously reported with in vivo drug administration. These techniques appear applicable for providing improved screening models to evaluate chemotherapeutic regimens for clinical use.

¹ Supported by Grant CA13141, from the National Cancer Institute, NIH, USPHS, and by the Medical Research Service of the Veterans Administration.

² Scholar, Leukemic Society of America, Inc. To whom requests for reprints should be addressed.

Received 3/19/76. Accepted 8/24/76.